Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

May 31, 2011

Conditions
Foot Ulcer, DiabeticDiabetic Foot
Interventions
DRUG

NorLeu3-A(1-7) in a gel formulation

Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.

Trial Locations (12)

16365

Warren General Hospital Wound Clinic, Warren

20007

Georgetown University Medical Center, Georgetown

24016

Professional Education and Research Institute, Roanoke

27834

Eastern Carolina Foot & Ankle Specialists, Greenville

62650

Passavant Area Hospital, Jacksonville

75224

Renaissance Hospital Dallas, Dallas

85723

Southern Arizona VA Health Care System, Tucson

85724

Southern Arizona Limb Salvage Alliance (SALSA), Tucson

94546

Bay Area Footcare, Castro Valley

92103-8896

University of California, San Diego, San Diego

91342-1438

Olive View - UCLA Medical Center, Sylmar

02118

Boston University School of Medicine, Boston

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Integra LifeSciences Corporation

INDUSTRY

lead

US Biotest, Inc.

INDUSTRY

NCT00796744 - Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers | Biotech Hunter | Biotech Hunter